{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:48:09Z","timestamp":1792082889869,"version":"4.4.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.msard.2023.105034","type":"journal-article","created":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T05:23:16Z","timestamp":1696137796000},"page":"105034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Dual positivity for anti-MOG and oligoclonal bands: Unveiling unique clinical profiles and implications"],"prefix":"10.1016","volume":"79","author":[{"given":"Esther","family":"Ganelin-Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahar","family":"Shelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Vaknin-Dembinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maayan","family":"Shachor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Rechtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Osherov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitsan","family":"Duvdevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayal","family":"Rozenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2023.105034_bib0001","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.105034_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103220","article-title":"Reinforcing the evidence of oligoclonal bands as a prognostic factor in patients with Multiple sclerosis","volume":"56","author":"Ben Noon","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2023.105034_bib0003","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. B."},{"issue":"6","key":"10.1016\/j.msard.2023.105034_bib0004","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/10408363.2022.2039591","article-title":"Oligoclonal bands: clinical utility and interpretation cues","volume":"59","author":"Carta","year":"2022","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"1","key":"10.1016\/j.msard.2023.105034_bib0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.105034_bib0006","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3389\/fimmu.2019.00726","article-title":"The cerebrospinal fluid in multiple sclerosis","volume":"10","author":"Deisenhammer","year":"2019","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.msard.2023.105034_bib0007","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/135245850100700503","article-title":"Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis","volume":"7","author":"Egg","year":"2001","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2023.105034_bib0008","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/brain\/awz144","article-title":"Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines","volume":"142","author":"Filippi","year":"2019","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.msard.2023.105034_bib0009","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1007\/s00415-018-9048-8","article-title":"2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes","volume":"265","author":"Gaetani","year":"2018","journal-title":"J. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2023.105034_bib0010","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1007\/s00415-020-10024-0","article-title":"Cell-based assays for the detection of MOG antibodies: a comparative study","volume":"267","author":"Gastaldi","year":"2020","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2023.105034_bib0011","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00415-009-5081-y","article-title":"MRI criteria in MS patients with negative and positive oligoclonal bands: equal fulfillment of Barkhof's criteria but different lesion patterns","volume":"256","author":"Huttner","year":"2009","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2023.105034_bib0012","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/medicina55060245","article-title":"Cerebrospinal fluid analysis in multiple sclerosis diagnosis: an update","volume":"55","author":"Lo Sasso","year":"2019","journal-title":"Medicina (Kaunas"},{"key":"10.1016\/j.msard.2023.105034_bib0013","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2023.105034_bib0014","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/1352458519871818","article-title":"Can CSF biomarkers predict future MS disease activity and severity?","volume":"26","author":"Magliozzi","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.105034_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.947630","article-title":"Positive predictive value of MOG-IgG for clinically defined MOG-AD within a real-world cohort","volume":"13","author":"Manzano","year":"2022","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2023.105034_bib0016","doi-asserted-by":"crossref","first-page":"e1047","DOI":"10.1212\/NXI.0000000000001047","article-title":"Predicting aggressive multiple sclerosis with intrathecal igm synthesis among patients with a clinically isolated syndrome","volume":"8","author":"Monreal","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.105034_bib0017","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.msard.2018.07.030","article-title":"Oligoclonal bands in multiple sclerosis; functional significance and therapeutic implications. Does the specificity matter?","volume":"25","author":"Pryce","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2023.105034_bib0018","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/02664760500079373","article-title":"The most-cited statistical papers","volume":"32","author":"Ryan","year":"2005","journal-title":"J. Appl. Stat."},{"issue":"6","key":"10.1016\/j.msard.2023.105034_bib0019","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jamaneurol.2021.0912","article-title":"Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing","volume":"78","author":"Sechi","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.105034_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2023.105034_bib0021","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.105034_bib0022","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s43055-023-01066-1","article-title":"MRI features of myelin oligodendrocyte glycoprotein antibody disease: a descriptive study\u2014how it differs from neuromyelitis optica spectrum disorders and multiple sclerosis","volume":"54","author":"Tom Mishael","year":"2023","journal-title":"Egypt J. Radiol. Nucl. Med."},{"key":"10.1016\/j.msard.2023.105034_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1211776","article-title":"Comparing clinical and imaging features of patients with MOG antibody-positivity and with and without oligoclonal bands","volume":"14","author":"Tomizawa","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2023.105034_bib0024","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823005357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823005357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T16:12:25Z","timestamp":1727453545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823005357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":24,"alternative-id":["S2211034823005357"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.105034","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual positivity for anti-MOG and oligoclonal bands: Unveiling unique clinical profiles and implications","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.105034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105034"}}